Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin otic solution - SALVAT

Drug Profile

Ciprofloxacin otic solution - SALVAT

Alternative Names: 0.2% Ciprofloxacin otic solution - SALVAT; CETRAXAL; DF-289; InfectoCipro; Ototopical ciprofloxacin; Unicexal

Latest Information Update: 11 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SALVAT
  • Class Anti-infectives; Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis externa
  • No development reported Otitis media

Most Recent Events

  • 11 Feb 2019 Ciprofloxacin otic solution is not yet available in Iceland for Otitis externa
  • 15 Mar 2016 Biomarkers information updated
  • 31 Aug 2015 No development reported - Phase-III for Otitis media (In children) in Spain, Denmark, Finland and Sweden (Otic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top